Remdesivir trial data ‘offers hope,’ says Gilead CEO
On the heels of an early announcement that coronavirus patients given Gilead’s Ebola drug remdesivir fared better than those who didn’t get the treatment, the company’s CEO, Daniel O’Day, deemed the results a cause for ‘hope at a time when it is badly needed,’ in an open letter obtained by Fox News. ‘Positive data’ from … Read more